Atlas Trials

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Clinical trial NCT02510794 · COMPLETED

Trial details

NCT number
NCT02510794
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Macular Degeneration
Start date
2015-09-28
Primary completion
2018-04-10
Enrollment
225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.